Clinical trials on another 1,600 people will start after the registration and will continue along with the production.
"It's a Sputnik moment", he told U.S. broadcaster CNN, referring to the launch in 1957 of the world's first space satellite by Russian Federation. Americans were surprised when they heard Sputnik's beeping. A US security official said the breach occurred in January and targeted the MA biotech firm's computer network.
There are also wide concerns the human testing of the vaccine is incomplete.
The Oxford University and British-Swedish firm AstraZeneca have developed the potential vaccine AZD1222, which has been found to generate an immune response and is safe. The second vaccine, being moved into advanced trials, targets the entire spike structure.
Both versions of Pfizer's vaccine elicit antibody responses as well as immune cells called T-cells, the company said. On Monday clinics around the United States began a Phase 3 trial of the vaccine candidate, with the aim of enrolling 30,000 people to test for safety and effectiveness.
A couple of weeks ago, two of the companies' four investigational vaccine candidates from its BNT162 mRNA-based vaccine program had received FDA Fast Track designation.
"The Ministry of Health in Russian Federation is following all necessary strict procedures". The director of the project, Alexander Ginsburg, has also stated that he himself has injected the vaccine into his own body. "The full impact of SARS-CoV-2 infection is not yet fully understood and we don't have highly effective therapies that are available to cure individuals who are infected in the challenge studies". The country now has more than 800,000 confirmed cases.
Trump cancels Republican convention activities in Jacksonville
President Donald Trump has made a decision to scrap the Republican Convention due to be held in the state next month. Trump acknowledged that consideration, saying, "I could see the media saying, 'Oh, this is very unsafe'".
Russian scientists say the vaccine is a modified version of an already-approved vaccine used to fight other diseases, meaning the safety of the product is already largely proven.
NPR reports the volunteers will be divided into two groups, one of which will be given two separate shots of the mRNA-1273 with around 28 days interval.
Officials say their scientific data is now being compiled and will be made available for peer review and publication in early August.
The conference also saw speakers from several leading research institutions in Europe as well representatives from collectives such as the Coalition for Epidemic Preparedness that are involved in myriad vaccine development projects.
The World Health Organization (WHO) has said that "this organism may be close wild-type and pathogenic, adapted and/or attenuated from wild-type with less or no pathogenicity, or genetically modified on some manner".
The vaccine entered the final stages of trials on Monday and is set to be tested on over 30,000 participants.